phase III clinical study

Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor

Isofol Medical Halts Colon Cancer Study After Negative Readout; Continues Subgroup Analyses

UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer

Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial

Novartis' Scemblix Nets European Approval for Subset of CML Patients

AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan

Emtora Nets $16.9M Grant to Advance Drug for Genetic Condition That Increases Colon Cancer Risk

Sanofi Ends Development of Breast Cancer Drug Amcenestrant

Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia

Bristol Myers Squibb, 2seventy Bio Eyeing Earlier-Line Multiple Myeloma Abecma Indication

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

FDA Approves Bristol Myers Squibb's Breyanzi for Second-Line Lymphoma Patients

Exelixis Launches Phase III Trial of XL092 in Certain Colorectal Cancer Patients

Recursion Launches Clinical Trial for Targeted Drug in NF2-Mutated Meningioma Patients